Evidence map›Paper›PMID 31822261›Full record

ArticleBMC bioinformatics2019

A computational approach based on the colored Petri net formalism for studying multiple sclerosis.

Simone Pernice, Marzio Pennisi, Greta Romano, Alessandro Maglione, Santina Cutrupi, Francesco Pappalardo, Gianfranco Balbo, Marco Beccuti, Francesca Cordero, Raffaele A Calogero

Open access · goldAbstract read
In one paragraph

Article in BMC bioinformatics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Simone PerniceDepartment of Computer Science, University of Turin, Turin, Italy.
Marzio PennisiDepartment of Mathematics and Computer Science, University of Catania, Catania, Italy.
Greta RomanoDepartment of Computer Science, University of Turin, Turin, Italy.
Alessandro MaglioneDepartment of Clinical and Biological Sciences, University of Turin, Orbassano, Italy.
Santina CutrupiDepartment of Clinical and Biological Sciences, University of Turin, Orbassano, Italy.
Francesco PappalardoDepartment of Drug Sciences, University of Catania, Catania, Italy.
Gianfranco BalboDepartment of Computer Science, University of Turin, Turin, Italy.
Marco BeccutiDepartment of Computer Science, University of Turin, Turin, Italy. beccuti@di.unito.it.ORCID http://orcid.org/0000-0001-6125-9460
Francesca CorderoDepartment of Computer Science, University of Turin, Turin, Italy.
Raffaele A CalogeroDepartment of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.
University of Turin · ITUniversity of Catania · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMultiple Sclerosis (MS) is an immune-mediated inflammatory disease of the Central Nervous System (CNS) which damages the myelin sheath enveloping nerve cells thus causing severe physical disability in patients. Relapsing Remitting Multiple Sclerosis (RRMS) is one of the most common form of MS in adults and is characterized by a series of neurologic symptoms, followed by periods of remission. Recently, many treatments were proposed and studied to contrast the RRMS progression. Among these drugs, daclizumab (commercial name Zinbryta), an antibody tailored against the Interleukin-2 receptor of T cells, exhibited promising results, but its efficacy was accompanied by an increased frequency of serious adverse events. Manifested side effects consisted of infections, encephalitis, and liver damages. Therefore daclizumab has been withdrawn from the market worldwide. Another interesting case of RRMS regards its progression in pregnant women where a smaller incidence of relapses until the delivery has been observed.

resultsIn this paper we propose a new methodology for studying RRMS, which we implemented in GreatSPN, a state-of-the-art open-source suite for modelling and analyzing complex systems through the Petri Net (PN) formalism. This methodology exploits: (a) an extended Colored PN formalism to provide a compact graphical description of the system and to automatically derive a set of ODEs encoding the system dynamics and (b) the Latin Hypercube Sampling with PRCC index to calibrate ODE parameters for reproducing the real behaviours in healthy and MS subjects.To show the effectiveness of such methodology a model of RRMS has been constructed and studied. Two different scenarios of RRMS were thus considered. In the former scenario the effect of the daclizumab administration is investigated, while in the latter one RRMS was studied in pregnant women.

conclusionsWe propose a new computational methodology to study RRMS disease. Moreover, we show that model generated and calibrated according to this methodology is able to reproduce the expected behaviours.

Indexed as

Computer SimulationMultiple Sclerosis, Relapsing-RemittingComputational BiologyDisease ProgressionFemaleHumansImmunosuppressive AgentsPregnancyRecurrenceImmunosuppressive AgentsColored petri netsComputational modelsMultiple sclerosisSensitivity analysis

Identifiers

PMID31822261
PMCPMC6904991
OpenAlexW2996373685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.